Skip to main content

Table 4 Medication exposure in SLE patients during 5-year follow-up after THAa

From: The impact of systemic lupus erythematosus on the risk of infection after total hip arthroplasty: a nationwide population-based matched cohort study

Medication Infection cases
(n = 37)
Non-infection cases
(n = 288)
P
Steroid
 Parenteral 2 (5.41) 33 (11.46) 0.399
 Oral 28 (75.68) 219 (76.04) 1
DMARDs-conventional
 Hydroxychloroquine 16 (43.24) 174 (60.42) 0.052
 Azathioprine 3 (8.11) 81 (28.13) 0.009
 Mycophenolate mofetil 0 (0.00) 9 (3.13)
 Ciclosporin 0 (0.00) 6 (2.08)
 Cyclophosphamide 2 (5.41) 10 (3.47) 0.634
 Methotrexate 2 (5.41) 15 (5.21) 1
DMARDs-biological
 Rituximab 0 (0.00) 0 (0.00)  
DMARDs type 1.38 ± 0.76 1.81 ± 0.97 0.002
  1. DMARDs disease-modifying antirheumatic drugs
  2. aData are presented as number and percentage